KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) EBT Margin (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed EBT Margin for 10 consecutive years, with 18810.88% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 1859278.0% to 18810.88% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 17392.93% through Dec 2025, down 1631051.0% year-over-year, with the annual reading at 17392.93% for FY2025, 1631051.0% down from the prior year.
  • EBT Margin hit 18810.88% in Q4 2025 for CRISPR Therapeutics AG, down from 11903.49% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 84.75% in Q2 2021 to a low of 2022866.67% in Q4 2022.
  • Historically, EBT Margin has averaged 132269.53% across 5 years, with a median of 15593.87% in 2025.
  • Biggest five-year swings in EBT Margin: plummeted -201884726bps in 2022 and later surged 202291119bps in 2023.
  • Year by year, EBT Margin stood at 4019.4% in 2021, then crashed by -50228bps to 2022866.67% in 2022, then skyrocketed by 100bps to 44.52% in 2023, then plummeted by -590bps to 218.1% in 2024, then crashed by -8525bps to 18810.88% in 2025.
  • Business Quant data shows EBT Margin for CRSP at 18810.88% in Q4 2025, 11903.49% in Q3 2025, and 23235.09% in Q2 2025.